GlobalData on MSN
MSD reports positive Phase III results for trial of Winrevair
MSD has announced positive Phase III HYPERION trial results showing Winrevair (sotatercept-csrk) reduced clinical worsening ...
GlobalData on MSN
MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate
Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.
Though Keytruda QLEX will be more patient-centric, analysts are sceptical of the drug’s capacity to stave off generic ...
Investors in Verona – a specialist in respiratory medicines – overwhelmingly gave their blessing to MSD's $107-per-share ...
The FDA has cleared the new version for across most of the solid tumour indications already granted for Keytruda, which is ...
A dedicated energy team is helping the global healthcare company to achieve net zero by 2045 Read more at The Business Times.
InvestorsHub on MSN
Evaxion Biotech Shares Jump Following MSD Vaccine Licensing Deal
Evaxion Biotech AS (NASDAQ:EVAX) surged 33% in premarket trading Thursday after announcing that MSD (NYSE:MRK) has exercised ...
Main Street Duncan has announced a partnership with Leadership Duncan Class 30 to change the city's Christmas parade route back to the traditional route. MSD said in a press release that due to “lack ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback